Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
ENTITY
SMARTSCORE: 3/5
Hanmi Science (008930 KS)
Watchlist
62
Analysis
Health Care
•
South Korea
Hanmi Science Co., Ltd. produces pharmaceutical products, including antibiotics, vitamins, and intestinal tonics. The Company also provides beverages and processes soft capsules for other pharmaceutical firms.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Hanmi Science
•
09 May 2024 12:19
Imminent Block Deals Involving Hanmi Science Shares Due to Inheritance Tax Payments
Reports indicate that the owners of Hanmi Science are poised to offload more than 50% of their stake to EQT Partners, securing approximately ₩1T....
Sanghyun Park
Follow
616 Views
Share
bullish
•
Quantitative Analysis
•
23 Jan 2024 22:58
Using Smartkarma's Smart Score Screener to Screen Alpha Generating Stocks in Korea
In this insight, we discuss using Smartkarma's new feature called Smart Score Screener to screen alpha generating stocks in Korea.
Douglas Kim
Follow
514 Views
Share
bullish
•
E Mart Inc
•
20 Feb 2025 08:23
Growing Importance of ACT - Korea's Largest Minority Shareholders Platform
In this insight, we discuss about the growing importance of ACT, the largest minority shareholders platform (https://www.act.ag/) in Korea with...
Douglas Kim
Follow
345 Views
Share
bullish
•
Thematic (Sector/Industry)
•
02 Feb 2025 00:30
APAC Healthcare Weekly (Feb 2)- Daiichi Sankyo, Eisai, Nippon Shinyaku, Shionogi, Celltrion
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...
Tina Banerjee
Follow
627 Views
Share
bullish
•
Cross Asset Strategy
•
09 Jan 2025 22:53
Korea Value Up Index: Winners and Losers in 2025 YTD
In this insight, we discuss the details of the share price performances of the Korea Value Up Index (especially among the index constituents) this...
Douglas Kim
Follow
465 Views
Share
1
2
3
4
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.52.8
x